CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.
  
  LEARNING OBJECTIVES

  • Evaluate published research establishing the efficacy and safety of Bruton tyrosine kinase (BTK) inhibitors as a component of first-line therapy for mantle cell lymphoma (MCL), and assess the current and potential clinical role of various BTK inhibitor-based strategies for patients newly diagnosed with the disease.
  • Identify patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) for whom the use of CD79b-targeted therapy as a component of first-line treatment would be appropriate.
  • Develop an understanding of available clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for DLBCL and follicular lymphoma (FL), and employ this information as part of patient education discussions.
  • Appraise the available research findings with and current clinical role of CD19-targeted antibody-drug conjugates in treatment for patients with R/R DLBCL.
  • Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor T-cell therapy for R/R DLBCL, FL and MCL, and counsel appropriately selected patients regarding the potential benefits of this therapeutic strategy.
  • Evaluate the available trial findings with bispecific antibodies targeting CD20 x CD3 in patients with FL and DLBCL, and determine the role of these agents in clinical management.
  • Recall new data with agents and strategies currently under investigation for various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 2.75 (audio) and 2.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2025/NHL/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ASCO2025/NHL/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASCO2025/NHL/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ASCO2025/NHL.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Joshua Brody, MD
  Director, Lymphoma Immunotherapy Program
  The Tisch Cancer Institute at Mount Sinai
  Faculty Member, Icahn Genomics Institute
  Icahn School of Medicine at Mount Sinai
  New York, New York
  
  No relevant conflicts of interest to disclose.
  
  Christopher Flowers, MD, MS
  Division Head, Division of Cancer Medicine
  Chair, Professor, Department of Lymphoma/Myeloma
  John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Karyopharm Therapeutics; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Alaunos Therapeutics, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, Foresight Diagnostics, National Cancer Institute, N-Power Medicine Inc, V Foundation.
  
  Ann LaCasce, MD, MMSc
  Associate Professor, Hematology and Medical Oncology
  Program Director, Dana-Farber/MGB Fellowship in Hematology/Oncology
  Dana-Farber Cancer Institute
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committees: Genmab US Inc, Kite, A Gilead Company; Consulting Agreements: Pierre Fabre.
  
  Tycel Phillips, MD, FASCO
  Associate Professor, Division of Lymphoma
  Department of Hematology and Hematopoietic Cell Transplantation
  City of Hope Comprehensive Cancer Center
  Duarte, California
  
  Advisory Committees: AbbVie Inc, Genentech, a member of the Roche Group,Genmab US Inc, Merck; Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Caribou Biosciences Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc, Xencor; Contracted Research: AbbVie Inc, Genentech, a member of the Roche Group, Sobi; Nonrelevant Financial Relationships: Leukemia & Lymphoma Society (LLS) Scholar in Clinical Research.
  
  MODERATOR
  Jeremy S Abramson, MD, MMSc
  Director, Center for Lymphoma
  Massachusetts General Hospital
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Allogene Therapeutics, Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, and Incyte Corporation.
  
  Release date: June 2025
  Expiration date: June 2026
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.